HeartSciences (HSCS) Liabilities and Shareholders Equity (2022 - 2026)

HeartSciences has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 32.45% year-over-year to $7.6 million; the trailing twelve-month figure through Jan 2026 stood at $24.2 million (down 22.34% YoY), and the FY2025 full-year result was $4.2 million, down 55.56% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $7.6 million, up from $6.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $10.8 million in Q1 2024, with the low at $2.1 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $5.6 million across 5 years, with a median of $5.6 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 228.38% — and 2025, when it plunged 55.56%.
• HeartSciences' Liabilities and Shareholders Equity stood at $4.8 million in 2022, then slumped by 50.36% to $2.4 million in 2023, then soared by 228.38% to $7.8 million in 2024, then fell by 22.9% to $6.0 million in 2025, then advanced by 25.99% to $7.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.6 million (Q1 2026), $6.0 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.